Research map: Associations of TILs and Genomic Alterations in HER2+ Early Breast Cancer

Back to the article

Papers in this map

  1. Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene · Dennis J. Slamon · 1987 · 11847 citations · Cited by this paper
  2. The NET score: an interpretable AI-assisted prognostic score for mortality risk in lung neuroendocrine tumors · 2026 · Related
  3. Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2 · Dennis J. Slamon · 2001 · 11633 citations · Cited by this paper
  4. Multiple endocrine neoplasia type 5: emerging evidence and clinical perspectives · 2026 · Related
  5. Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer · Sunil Verma · 2012 · 3861 citations · Cited by this paper
  6. TERT promoter mutations and recurrence patterns in differentiated thyroid carcinoma · 2026 · Related
  7. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014 · Roberto Salgado · 2014 · 3227 citations · Cited by this paper
  8. Is preoperative adrenoceptor blockade necessary in patients with paraganglioma? · 2026 · Related
  9. Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer · Sandra M. Swain · 2015 · 2188 citations · Cited by this paper
  10. Whole genome and exome sequencing of pancreatic NET to investigate PRRT response · 2026 · Related
  11. Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98 · Sherene Loi · 2013 · 1677 citations · Cited by this paper
  12. The role of the B7 family in autoimmune thyroid diseases and thyroid cancer · 2026 · Related
  13. A Functional Genetic Approach Identifies the PI3K Pathway as a Major Determinant of Trastuzumab Resistance in Breast Cancer · Katrien Berns · 2007 · 1639 citations · Cited by this paper
  14. Developing an epithelial signature for prognosis of papillary thyroid carcinoma · 2026 · Related
  15. World Medical Association Declaration of Helsinki · World Medical Association · 2024 · 1497 citations · Cited by this paper
  16. Ageing and pituitary neuroendocrine tumours (PitNETs): from bench to bedside · 2026 · Related
  17. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial · Sherene Loi · 2014 · 1285 citations · Cited by this paper
  18. Adrenocortical cell and macrophage heterogeneity at single-cell spatial resolution in KCNJ5 -mutant aldosterone-producing adenomas · 2026 · Related
  19. Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/ neu –Positive Metastatic Breast Cancer · Antonino Musolino · 2008 · 969 citations · Cited by this paper
  20. NP-101 in combination with nivolumab and ipilimumab in metastatic extrapulmonary neuroendocrine carcinomas (EP-NECs): A pilot study · 2026 · Related
  21. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers · Mark Daniel Pegram · 1999 · 694 citations · Cited by this paper
  22. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO–College of American Pathologists Guideline Update · Antonio C. Wolff · 2023 · 680 citations · Cited by this paper
  23. Overall Survival Benefit With Lapatinib in Combination With Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: Final Results From the EGF104900 Study · Kimberly Blackwell · 2012 · 553 citations · Cited by this paper
  24. PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab · S. Loibl · 2016 · 237 citations · Cited by this paper
  25. Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0 · Sara M. Tolaney · 2021 · 236 citations · Cited by this paper
  26. Immune Gene Expression Is Associated with Genomic Aberrations in Breast Cancer · Anton Mikhailovich Safonov · 2017 · 164 citations · Cited by this paper
  27. Role of exon-16-deleted HER2 in breast carcinomas · Fabio Castiglioni · 2006 · 147 citations · Cited by this paper
  28. Treatment of HER2-overexpressing breast cancer · José Baselga · 2010 · 146 citations · Cited by this paper
  29. Cancer-immune interactions in ER-positive breast cancers: PI3K pathway alterations and tumor-infiltrating lymphocytes · Marcelo Sobral‐Leite · 2019 · 136 citations · Cited by this paper
  30. Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-Stage HER2-Positive Breast Cancer · Rim S. Kim · 2019 · 57 citations · Cited by this paper
  31. Genomic correlates of response to adjuvant trastuzumab (H) and pertuzumab (P) in HER2+ breast cancer (BC): Biomarker analysis of the APHINITY trial. · Ian E. Krop · 2019 · 50 citations · Cited by this paper
  32. Aiming at a Tailored Cure for ERBB2 -Positive Metastatic Breast Cancer · Paolo Tarantino · 2022 · 40 citations · Cited by this paper
  33. Tumor-infiltrating lymphocytes in HER2-positive breast cancer: potential impact and challenges · Ilana Miriam Schlam · 2025 · 34 citations · Cited by this paper
  34. The immune profile of small HER2-positive breast cancers: a secondary analysis from the APT trial · Romualdo Barroso‐Sousa · 2019 · 30 citations · Cited by this paper
  35. PIK3CA Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2+ Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype · Valentina Guarneri · 2020 · 23 citations · Cited by this paper
  36. Genetic mutations in HER2-positive breast cancer: possible association with response to trastuzumab therapy · Nermine H. Zakaria · 2023 · 18 citations · Cited by this paper
  37. Clinicopathological Features, Tumor Mutational Burden, and Tumour-Infiltrating Lymphocyte Interplay in ERBB2-Mutated Breast Cancer: In Silico Analysis · Shiro Uchida · 2021 · 10 citations · Cited by this paper
  38. Identification of genetic and immune signatures for the recurrence of HER2-positive breast cancer after trastuzumab-based treatment · Chi Xu · 2023 · 3 citations · Cited by this paper
  39. 239MO TILs and overall survival (OS) in HER2+ early breast cancer (eBC): 10-year (yr) updated analysis of the ShortHER trial · Maria Vittoria Dieci · 2024 · 2 citations · Cited by this paper

Source: OpenAlex (CC0)